Clinuvel Pharmaceuticals Limited (CUVL)
NASDAQ
CUVL price, last 12 months
Key stats
- Previous close
- $5.78
- Open
- $5.82
- Day range
- $5.60 – $5.82
- 52-week range
- $5.60 – $8.20
- Volume
- 13.3K
- Avg volume (20 days)
- 26K
- Market cap
- $283.9M
Performance
Technicals and fundamentals
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
- Listed on
- NASDAQ
- Market cap
- $283.9M